Middle Branch Partners' Larry Barr and Chuck Weikel review MedTech M&A at mid-2026: deal volume holds steady even as transactions shrink in size, valuations climb on quality over scale, and cross-border deals face tariff-driven friction while domestic activity stays smooth. Lending is available but more selectively deployed. On AI, both find rare agreement: real technology, not yet a real M&A driver.